CSL Behring GmbH

Most patients are interested in exploring more convenient treatment options. CSL Behring has identified what it will take to win in a major autoimmune market. Ahead of a potential approval of argenx’s rival drug, the company surveyed people with chronic inflammatory demyelinating polyneuropathy (CIDP)—and emerged with evidence of an appetite for more convenient treatments. The existing treatment options in CIDP include a pair of CSL products, the intravenous Privigen and the subcutaneous, self-administered Hizentra. Use of Hizentra is limited to maintenance therapy. Later this year, argenx expects to win FDA approval for Vyvgart Hytrulo, a subcutaneous product with a different mechanism of action. The drug will provide competition to products that drove growth at CSL last year. CSL commissioned Harris Poll to help understand what factors will determine the winners of the next era of the CIDP market. The survey included 100 people living with the condition, including 98 who were on treatment, and 100 specialist physicians who regularly see at least one CIDP patient. Most (82%) patients are interested in exploring more convenient treatment options. Administering the drug at home, something made possible by Hizentra, is extremely or very important to 72% of the respondents. Home administration trailed the three non-negotiables—efficacy, minimal side effects and condition maintenance—on the list of priorities when patients consider new therapies.  While patients are open to new therapies, some encouragement and education may be needed to get people to seek out alternatives to their current treatments. Less than half of the respondents discuss new treatment options and switching drugs with their physicians, and similarly few people have a good grasp of how different therapies work and are administered.  CSL, which is set to start selling a higher dose of Hizentra, is pitching its subcutaneous product as the answer to demands for more convenient treatment options. Argenx’s FcRn drug Vyvgart Hytrulo, which is given subcutaneously but must be administered by a healthcare professional in its existing indication, is on track to win approval in CIDP and launch in the U.S. around the middle of the year. At an investor event in October, Andy Schmeltz, executive vice president of the CSL Behring business unit, said he expects Privigen and Hizentra “to maintain compelling leadership positions in CIDP and in all core indications given their well-established and well characterized benefit risk profile, their proven long-term protection, physician clinical experience and strong placement in treatment guidelines.”  Schmeltz added that “in CIDP, in particular, we look forward to competing with FcRns, both offensively and defensively, reinforcing the compelling benefit risk profile of Ig therapy.” CSL has a lot riding on the products. Privigen and Hizentra brought in (PDF) $2.8 billion and $1.6 billion, respectively, in the year ended 30 June. The figures represented 29% growth for Privigen and 12% growth for Hizentra.

DUBLIN, May 8, 2023 /PRNewswire/ -- The "Pharmacovigilance USA Congress 2023" conference has been added to ResearchAndMarkets.com's offering. After witnessing outstanding success in our previous Pharmacovigilance conferences, Pharmacovigilance USA 2023 will gather the top notch Industry experts from Pharma/Biotech and Clinical Research Organisations. Why Attend This Conference? Listen to the top notch Pharma/Biotech Industry pioneers who will deliver the latest cutting edge information. A fantastic opportunity to network with the top notch Pharma/Biotech Industry pioneers during the networking sessions. Speak-out sessions and Panel discussions will provide a great opportunity to ask questions from the expert and find out feasible solutions. Current Market Of Global Pharmacovigilance 6 Billion Pharmacovigilance Market to reach $8 Billion in 2025 1,053 Billion Global Pharmaceutical Market Value $1057 Billion Come and Update with the expanding Global Pharmaceutical Industry and increase awareness on the significant and essential need of Global Pharmacovigilance. Why Attend Pharmacovigilance USA A Global Event In Pharmacovigilance Ensuring Pharmacovigilance For Global Public Health 20+ Expert Speakers From Around The World 100's Pharma/ Biotech Professionals From Over 50 Countries Bringing Together The Key Decision Makers Under One Roof Over 10 Hours Of Dedicated Networking And Interactive Sessions Who Should Attend: Pharmacovigilance USA Congress 2023 attracts senior-level attendees from leading pharmaceutical, biopharmaceutical, biotechnology, diagnostics, CRO and solution provider companies. Delegates include VPs, Directors, Heads, Managers, Scientific Advisors, Consultants, Senior scientists and professionals with intermediate to advance knowledge and experience in the following. Pharmacovigilance Risk Management Drug Safety Pharmacoepidemiology Drug Research & Development Clinical Pharmacology Clinical Safety Information And Clinical Data Management Medical Product Safety Assessment Clinical Research & Safety Data Analysis Information Technology Medical Information Health Outcomes Sales And Marketing Clinical Trials & CRO's Contract Manufacturing Speakers Narayan Nair FDA - USA Lana Gloukhova ATHIRA PHARMA - USA Samirah Qureshi ALEXION - USA Reema Mehta PFIZER - USA Jenifer Kane ENTASIS THERAPEUTICS - USA Michael Bean Johnson & Johnson Khaudeja Bano AMGEN - USA Dawn Mucci JAZZ PHARMACEUTICALS - USA Richard Wolf CSL Behring USA Jaylaxmi Nalawade LUPIN PHARMACEUTICALS - USA Michael Von Forstner BIOGEN - USA Dennis L. Virgo AKEBIA THERAPEUTICS - USA Dr Bert P Van Leeuwen Astellas Pharma Alina Tudor M.D. Norgine Dr Jackie Roberts Accord HealthCare Edita Kaupiene, MPharm Pharmacovigilance Project Manager Manjit Virdee GSK Budhesh Dhamija CSL Behring GmbH, Germany Giovanni Furlan PFIZER Raj Bhogal Takeda For more information about this conference visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

DUBLIN--( BUSINESS WIRE )--The "Pharmacovigilance USA Congress 2023" conference has been added to ResearchAndMarkets.com's offering. After witnessing outstanding success in our previous Pharmacovigilance conferences, Pharmacovigilance USA 2023 will gather the top notch Industry experts from Pharma/Biotech and Clinical Research Organisations. Why Attend This Conference? Listen to the top notch Pharma/Biotech Industry pioneers who will deliver the latest cutting edge information. A fantastic opportunity to network with the top notch Pharma/Biotech Industry pioneers during the networking sessions. Speak-out sessions and Panel discussions will provide a great opportunity to ask questions from the expert and find out feasible solutions. Current Market Of Global Pharmacovigilance 6 Billion Pharmacovigilance Market to reach $8 Billion in 2025 1,053 Billion Global Pharmaceutical Market Value $1057 Billion Come and Update with the expanding Global Pharmaceutical Industry and increase awareness on the significant and essential need of Global Pharmacovigilance. Why Attend Pharmacovigilance USA A Global Event In Pharmacovigilance Ensuring Pharmacovigilance For Global Public Health 20+ Expert Speakers From Around The World 100's Pharma/ Biotech Professionals From Over 50 Countries Bringing Together The Key Decision Makers Under One Roof Over 10 Hours Of Dedicated Networking And Interactive Sessions Who Should Attend: Pharmacovigilance USA Congress 2023 attracts senior-level attendees from leading pharmaceutical, biopharmaceutical, biotechnology, diagnostics, CRO and solution provider companies. Delegates include VPs, Directors, Heads, Managers, Scientific Advisors, Consultants, Senior scientists and professionals with intermediate to advance knowledge and experience in the following. Pharmacovigilance Risk Management Drug Safety Pharmacoepidemiology Drug Research & Development Clinical Pharmacology Clinical Safety Information And Clinical Data Management Medical Product Safety Assessment Clinical Research & Safety Data Analysis Information Technology Medical Information Health Outcomes Sales And Marketing Clinical Trials & CRO's Contract Manufacturing Speakers Narayan Nair FDA - USA Lana Gloukhova ATHIRA PHARMA - USA Samirah Qureshi ALEXION - USA Reema Mehta PFIZER - USA Jenifer Kane ENTASIS THERAPEUTICS - USA Michael Bean Johnson & Johnson Khaudeja Bano AMGEN - USA Dawn Mucci JAZZ PHARMACEUTICALS - USA Richard Wolf CSL Behring USA Jaylaxmi Nalawade LUPIN PHARMACEUTICALS - USA Michael Von Forstner BIOGEN - USA Dennis L. Virgo AKEBIA THERAPEUTICS - USA Dr Bert P Van Leeuwen Astellas Pharma Alina Tudor M.D. Norgine Dr Jackie Roberts Accord HealthCare Edita Kaupiene, MPharm Pharmacovigilance Project Manager Manjit Virdee GSK Budhesh Dhamija CSL Behring GmbH, Germany Giovanni Furlan PFIZER Raj Bhogal Takeda For more information about this conference visit https://www.researchandmarkets.com/r/lpprae About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.